Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 3, 2008, Pages 529-537

  Sai, Kimie ^a   Saito, Yoshiro ^a   Fukushima Uesaka, Hiromi ^a   Kurose, Koichi ^a   Kaniwa, Nahoko ^a   Kamatani, Naoyuki ^b   Shirao, Kuniaki ^c,d   Yamamoto, Noboru ^c   Hamaguchi, Tetsuya ^c   Kunitoh, Hideo ^c   Ohe, Yuichiro ^c   Tamura, Tomohide ^c   Yamada, Yasuhide ^c   Minami, Hironobu ^e,f   Ohtsu, Atsushi ^e   Yoshida, Teruhiko ^g   Saijo, Nagahiro ^e   Sawada, Jun Ichi ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d OITA UNIVERSITY   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f KOBE UNIVERSITY HOSPITAL   (Japan)

^g NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

CYP3A4; Haplotype; Irinotecan; Pharmacogenetics

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; AMRUBICIN; CISPLATIN; CYTOCHROME P450 3A4; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MITOMYCIN C;

ADULT; AGED; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; COLON CANCER; DIARRHEA; DISEASE SEVERITY; DRUG CLEARANCE; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEOPLASM; NEUTROPENIA; PRIORITY JOURNAL; SEX DIFFERENCE; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; CYTOCHROME P-450 CYP3A; FEMALE; HAPLOTYPES; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS; POLYMORPHISM, GENETIC; PRODRUGS; SEX FACTORS;

EID: 45849135654     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0634-1     Document Type: Article

References (34)

1. Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921-6916
2. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 299:825-831
3. de Forni M, Bugat R, Chabot GG, Culine S, Extra JM, Gouyette A, Madelaine I, Marty ME, Mathieu-Boue A (1994) Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354
4. Fukushima-Uesaka H, Saito Y, Watanabe H, Shiseki K, Saeki M, Nakamura T, Kurose K, Sai K, Komamura K, Ueno K, Kamakura S, Kitakaze M, Hanai S, Nakajima T, Matsumoto K, Saito H, Goto Y, Kimura H, Katoh M, Sugai K, Minami N, Shirao K, Tamura T, Yamamoto N, Minami H, Ohtsu A, Yoshida T, Saijo N, Kitamura Y, Kamatani N, Ozawa S, Sawada J (2004) Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population. Hum Mutat 23:100
5. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 139:1-17
6. Haaz MC, Rivory L, Riche C, Vernillet L, Robert J (1998) Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 58:468-472
7. Haaz MC, Riche C, Rivory LP, Robert J (1998) Biosynthesis of an aminopiperidino metabolite of irinotecan [7-ethyl-10-[4-(1-piperidino)-1- piperidino]carbonyloxycamptothecine] by human hepatic microsomes. Drug Metab Dispos 26:769-774
8. Han JY, Lim HS, Shin ES, Yoo YK, Park YH, Lee JE, Jang IJ, Lee DH, Lee JS (2006) Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J Clin Oncol 24:2237-2244
9. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 99:1290-1295
10. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, Nuessler AC, Neuhaus P, Klattig J, Eiselt R, Koch I, Zibat A, Brockmoller J, Halpert JR, Zanger UM, Wojnowski L (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-779
11. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. Clin Oncol 22:1382-1388
12. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 15:847-854
13. Iyer L, Das S, Janisch L, Wen M, Ramirez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47
14. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A (2002) Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 20:3122-3129
15. Kitamura Y, Moriguchi M, Kaneko H, Morisaki H, Morisaki T, Toyama K, Kamatani N (2002) Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 66:183-193
16. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K (2001) Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
17. Lamba JK, Lin YS, Schuetz EG, Thummel KE (2002) Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271-1294
18. Martinez-Jimenez CP, Jover R, Donato MT, Castell JV, Gomez-Lechon MJ (2007) Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab 8:185-194
19. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A (2002) Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 94:1247-1249
20. Mathijssen RH, Marsh S, Karlsson MO, Xie R, Baker SD, Verweij J, Sparreboom A, McLeod HL (2003) Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 9:3246-3253
21. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T, de Bruijn P, Graveland WJ, Figg WD, Verweij J, Sparreboom A (2004) Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 96:1585-1592
22. Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: Roles of UGT1A1*6 and*28. Pharmacogenet Genomics 17:497-504
23. Murayama N, Nakamura T, Saeki M, Soyama A, Saito Y, Sai K, Ishida S, Nakajima O, Itoda M, Ohno Y, Ozawa S, Sawada J (2002) CYP3A4 gene polymorphisms influence testosterone 6-beta-hydroxylation. Drug Metab Pharmacokinet 7:150-156
24. Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, Ozawa S, Aoyagi N, Kamatani N, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Yoshida T, Minami H, Saijo N, Katori N, Sawada J (2006) Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer. Clin Pharmacol Ther 80:179-191
25. Sai K, Kaniwa N, Ozawa S, Sawada J (2002) An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. Biomed Chromatogr 16:209-218
26. Sai K, Saeki M, Saito Y, Ozawa S, Katori N, Jinno H, Hasegawa R, Kaniwa N, Sawada J, Komamura K, Ueno K, Kamakura S, Kitakaze M, Kitamura Y, Kamatani N, Minami H, Ohtsu A, Shirao K, Yoshida T, Saijo N (2004) UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 75:501-515
27. Santos A, Zanetta S, Cresteil T, Deroussent A, Pein F, Raymond E, Vernillet L, Risse ML, Boige V, Gouyette A, Vassal G (2000) Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 6:2012-2020
28. Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC (1997) Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164
29. Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Persheck CV, Lord RS III (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [14C]CPT-11 in cancer patients. Drug Metab Dispos 28:423-433
30. Smith NF, Figg WD, Sparreboom A (2006) Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro 20:163-175
31. Wrighton SA, VandenBranden M, Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461-473
32. Wolbold R, Klein K, Burk O, Nussler AK, Neuhaus P, Eichelbaum M, Schwab M, Zanger UM (2003) Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38:978-988
33. Wojnowski L, Kamdem LK (2006) Clinical I mplications of CYP3A polymorphisms. Expert Opin Drug Metab Toxicol 2:171-182
34. Yong WP, Ramirez J, Innocenti F, Ratain MJ (2005) Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res 11:6699-6704